Briefcase

Best Practices for Incorporating LAIs into Treatment Planning for Schizophrenia

Launch Date
12/29/2020
Credit Amount
0.00 Expired
Credit Expires
12/29/2021
This activity is part of a series

Faculty

John M. Kane, MD
Senior Vice President, Behavioral Health Services, Northwell Health
Chairman, Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY
Professor and Chairman of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY
John M. Kane, MD

John M. Kane, MD, is the Senior Vice President for Behavioral Health Services at Northwell Health (formerly North Shore-Long Island Jewish Health System) in New Hyde Park, New York. He is Chairman of the Department of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York. Additionally, he is Professor and Chairman of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

Dr. Kane earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Kane is the recipient of many awards, including the Lieber Prize, the American Psychiatric Association’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, and the Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society and the Schizophrenia International Research Society.

Dr. Kane has been the principal investigator for research projects focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 600 peer-reviewed papers and serves on the editorial boards of numerous journals.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Schizophrenia is an all-too-often chronic, debilitating disorder that impedes quality of life and psychosocial functioning. Implementation of effective therapy that promotes sustained recovery often poses a challenge for both clinicians and patients. Long-acting injectables (LAIs) can play a critical role in relapse prevention and rehospitalization, and subsequently, recovery and restoration of function.

This CME Outfitters BriefCase will guide clinicians through best practices to identify patients with schizophrenia who are ideal candidates for LAIs as well as effective communication strategies to facilitate the discussion of using LAIs in these patients.

Learning Objectives

At the end of this CME/CE activity, participants should be able to identify patients with schizophrenia who are ideal candidates for LAI therapies and strategies for transitioning from oral therapies.

The following learning objectives pertain only to those requesting CNE or CPE credit: Identify patients with schizophrenia who are ideal candidates for LAI therapies and strategies for transitioning from oral therapies.

Financial Support

Supported by an educational grant from Otsuka America Pharmaceutical, Inc., and Lundbeck.

Target Audience

Psychiatrists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-20-119-H01-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kane reports that he receives grants from Janssen Pharmaceuticals, Inc.; Lundbeck; and Otsuka America Pharmaceutical, Inc. He is a consultant for ACADIA Pharmaceuticals Inc.; Alkermes; Allergan; F. Hoffmann-La Roche; Intra-Cellular Therapies, Inc.; Lundbeck; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Johnson & Johnson; LB Pharmaceuticals, Inc.; Merck & Co., Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Reviva Pharmaceuticals Inc.; Saladax Biomedical, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teva. He is a stock shareholder of Vanguard Research Group; and LB Pharmaceuticals, Inc.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Michael J. Franks, MSN, AGACNP-BC, FNP-BC (peer reviewer)
  • Mae Ochoa, RPh (peer reviewer)
  • Kashemi D. Rorie, PhD (planning committee)
  • Evan Luberger (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-119-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

BC-030-122820-41

Best Practices for Incorporating LAIs into Treatment Planning for Schizophrenia
Event Date: 12/29/2020

Activities in the Series

12/29/2020

From Bench to Bedside: Applying Clinical Updates to Schizophrenia Management

0.00 Expired
Learn More